# Comparison of Adverse Reactions Between Remimazolam and Propofol in Hysteroscopic Surgery in Mainland China: A Meta‐Analysis and Systematic Review

**Authors:** Zirui Liu, Kexu Zhu, Zidong Zhao, Qi Zeng

PMC · DOI: 10.1155/anrp/4206976 · Anesthesiology Research and Practice · 2026-01-06

## TL;DR

This study compares remimazolam and propofol for hysteroscopic surgery anesthesia, finding remimazolam reduces certain adverse reactions.

## Contribution

A meta-analysis showing remimazolam lowers risks of specific adverse reactions compared to propofol in hysteroscopic procedures.

## Key findings

- Remimazolam significantly reduces respiratory depression compared to propofol.
- Patients using remimazolam experience less dizziness and postoperative nausea.
- No significant difference in anesthesia recovery time between the two drugs.

## Abstract

The purpose of this meta‐analysis was to compare the adverse reactions of remimazolam and propofol in hysteroscopic anesthesia and to evaluate the efficacy of remimazolam in alleviating adverse reactions.

We conducted a database search using China National Knowledge Infrastructure (CNKI), PubMed, and the Cochrane Library to identify randomized controlled trials (RCTs) comparing the use of remimazolam with propofol for hysteroscopy procedures. We extracted data on the occurrence of adverse reactions such as hypotension, respiratory depression, dizziness, nausea, and vomiting for meta‐analysis. Literature published until July 2024 was screened from each database, and the quality of the included studies was assessed using the bias risk assessment tool recommended by Cochrane. Data analysis was performed using RevMan 5.3 software, developed by the Cochrane Collaboration in the United Kingdom.

The pooled results demonstrated significant differences in favor of remimazolam when compared to propofol for procedural sedation. Patients receiving remimazolam showed a lower risk of respiratory depression (RR: 0.19; 95% CI: [0.11, 0.33]; I
2 = 0%; p < 0.00001), dizziness (RR: 0.10; 95% CI: [0.04, 0.31]; I
2 = 0%; p < 0.0001), and postoperative nausea and vomiting (RR: 0.60; 95% CI: [0.15, 2.46]; I
2 = 0%; p = 0.48). No significant differences were observed in anesthesia recovery time between the remimazolam and propofol groups (MD: −0.07; 95% CI: [−0.18–1.04]; I
2 = 98%; p = 0.90).

Compared to propofol, remimazolam reduces the occurrence of hypotension, respiratory depression, dizziness, and postoperative nausea and vomiting in the anesthesia management of hysteroscopy procedures.

## Linked entities

- **Chemicals:** remimazolam (PubChem CID 9867812), propofol (PubChem CID 4943)

## Full-text entities

- **Diseases:** vomiting (MESH:D014839), respiratory depression (MESH:D012131), hypotension (MESH:D007022), postoperative nausea and vomiting (MESH:D020250), dizziness (MESH:D004244), nausea (MESH:D009325)
- **Chemicals:** Remimazolam (MESH:C522201), Propofol (MESH:D015742)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12771604/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12771604/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12771604/full.md

---
Source: https://tomesphere.com/paper/PMC12771604